Bellerophon Therapeutics, Inc. (BLPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bellerophon Therapeutics, Inc. (BLPH) trades at $0.012 with AI Score 44/100 (Grade C). Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiopulmonary diseases. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for BLPH: BLPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BLPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BLPH: the 3 scored disciplines are evenly split. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Bellerophon Therapeutics, Inc. (BLPH) Healthcare & Pipeline Overview
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in cardiopulmonary disease treatments, primarily pulmonary hypertension. Their lead product, INOpulse, utilizes a proprietary pulsatile nitric oxide delivery system, currently in Phase 3 trials for fibrotic interstitial lung disease, positioning them in a niche within the broader biotechnology sector.
What Is the Investment Thesis for BLPH?
Bellerophon Therapeutics' investment thesis hinges on the successful development and commercialization of INOpulse for pulmonary hypertension associated with fibrotic interstitial lung disease (PH-ILD). The ongoing Phase 3 trial represents a critical value driver. Positive trial results and subsequent FDA approval could unlock a significant market opportunity. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and the need for additional capital. The company's market capitalization is $0.00B, reflecting the high-risk, high-reward nature of clinical-stage biotechnology companies. Investors should closely monitor clinical trial data and regulatory milestones to assess the viability of this investment.
Based on FMP financials and quantitative analysis
BLPH Key Highlights
- INOpulse is in Phase 3 clinical trial for pulmonary hypertension associated with fibrotic interstitial lung disease (PH-ILD).
- INOpulse completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
- INOpulse completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis.
- The company's focus is on cardiopulmonary diseases, specifically pulmonary hypertension.
- Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, New Jersey.
Who Are BLPH's Competitors?
BLPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| BLRX BioLineRx Ltd. | $2.92 | +3.18% | $12.7M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.02 | -1.95% | $165M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BLPH's Key Strengths?
- Proprietary INOpulse technology.
- Focus on a specific therapeutic area (pulmonary hypertension).
- Clinical-stage pipeline with ongoing Phase 3 trial.
- Experienced management team.
What Are BLPH's Weaknesses?
- Limited financial resources.
- Reliance on a single product candidate (INOpulse).
- High risk of clinical trial failure.
- Dependence on regulatory approvals.
What Could Drive BLPH Stock Higher?
- Announcement of topline results from the Phase 3 clinical trial of INOpulse for pulmonary hypertension associated with fibrotic interstitial lung disease (PH-ILD).
- Continued enrollment and progress in the Phase 3 clinical trial of INOpulse for PH-ILD.
- Potential regulatory submissions and approvals for INOpulse in the United States and other markets.
- Development and expansion of the INOpulse platform for other cardiopulmonary indications.
What Are the Key Risks for BLPH?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure of the Phase 3 clinical trial of INOpulse to meet its primary endpoints.
- Regulatory delays or rejection of INOpulse by the FDA and other agencies.
- Competition from existing and emerging therapies for pulmonary hypertension.
- Difficulty raising additional capital to fund clinical development and commercialization activities.
- Intellectual property challenges or infringement claims.
What Are the Growth Opportunities for BLPH?
- Expansion into New Therapeutic Areas: Bellerophon has the opportunity to expand the application of its INOpulse technology beyond pulmonary hypertension associated with fibrotic interstitial lung disease (PH-ILD) to other cardiopulmonary conditions. This includes exploring its use in treating pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), sarcoidosis, and other related diseases. Success in these areas could significantly broaden the market for INOpulse and drive revenue growth.
- Geographic Expansion: Currently focused on the United States, Bellerophon can pursue geographic expansion into Europe and other international markets. Obtaining regulatory approvals in these regions would allow the company to tap into a larger patient population and increase revenue streams. This expansion would require strategic partnerships and significant investment in clinical trials and regulatory affairs. The timeline for international expansion would depend on regulatory pathways and market access strategies.
- Strategic Partnerships and Licensing Agreements: Bellerophon can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of INOpulse. These partnerships can provide access to additional funding, expertise, and distribution networks. Licensing agreements can generate upfront payments and royalties on future sales. Identifying the right partners and negotiating favorable terms are critical for maximizing the value of these collaborations.
- Advancements in Delivery Technology: Bellerophon can continue to innovate and improve its INOpulse delivery technology to enhance its efficacy, safety, and ease of use. This includes exploring new delivery methods, optimizing the pulsatile nitric oxide delivery profile, and developing user-friendly devices. These advancements can further differentiate INOpulse from competing therapies and strengthen its competitive advantage. The timeline for these technological advancements would depend on research and development efforts and regulatory approvals.
- Orphan Drug Designation and Market Exclusivity: Bellerophon can leverage orphan drug designation for INOpulse in specific pulmonary hypertension indications to gain market exclusivity and other regulatory benefits. Orphan drug designation provides incentives such as tax credits, reduced regulatory fees, and a period of market exclusivity, which can protect the company's investment and enhance its profitability. The timeline for obtaining orphan drug designation depends on the specific indication and regulatory requirements.
What Opportunities Does BLPH Have?
- Expansion into new therapeutic areas.
- Geographic expansion into international markets.
- Strategic partnerships and licensing agreements.
- Advancements in delivery technology.
What Threats Does BLPH Face?
- Competition from existing pulmonary hypertension treatments.
- Unfavorable clinical trial results.
- Regulatory delays or rejection.
- Difficulty raising additional capital.
What Are BLPH's Competitive Advantages?
- Proprietary INOpulse technology: A unique pulsatile nitric oxide delivery system.
- Patent protection: Intellectual property rights covering INOpulse and its applications.
- Clinical trial data: Demonstrating the safety and efficacy of INOpulse in specific indications.
- Regulatory expertise: Navigating the complex regulatory approval process for new drugs.
What Does BLPH Do?
Bellerophon Therapeutics, Inc., founded in 2009 and headquartered in Warren, New Jersey, is a clinical-stage therapeutics company dedicated to developing innovative treatments for cardiopulmonary diseases. The company's core focus is on pulmonary hypertension, a condition characterized by high blood pressure in the arteries leading to the lungs. Their primary product candidate, INOpulse, is a proprietary pulsatile nitric oxide delivery system designed to improve the efficacy and safety of nitric oxide therapy. INOpulse is currently in Phase 3 clinical trials for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease (PH-ILD). The company has also completed Phase 2a clinical trials for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, chronic thromboembolic pulmonary hypertension, and pulmonary hypertension associated with pulmonary edema from high altitude sickness. Bellerophon aims to address unmet medical needs in cardiopulmonary diseases by leveraging its innovative INOpulse technology to deliver targeted and efficient nitric oxide therapy.
What Products and Services Does BLPH Offer?
- Develops products for the treatment of cardiopulmonary diseases.
- Focuses on pulmonary hypertension treatments.
- Utilizes INOpulse, a proprietary pulsatile nitric oxide delivery platform.
- Conducts clinical trials for various pulmonary hypertension indications.
- Aims to improve the efficacy and safety of nitric oxide therapy.
- Targets unmet medical needs in cardiopulmonary diseases.
How Does BLPH Make Money?
- Develops and patents innovative drug delivery technologies.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA and other agencies.
- Commercializes approved products through direct sales or partnerships.
What Industry Does BLPH Operate In?
Bellerophon Therapeutics operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products. The pulmonary hypertension market is a growing segment within the broader cardiovascular therapeutics market. The competitive landscape includes companies developing various treatments for pulmonary hypertension, such as vasodilators and other targeted therapies. Bellerophon's INOpulse technology aims to differentiate itself through its pulsatile nitric oxide delivery system, potentially offering improved efficacy and safety compared to existing treatments.
Who Are BLPH's Key Customers?
- Patients with pulmonary hypertension.
- Hospitals and clinics treating cardiopulmonary diseases.
- Physicians specializing in pulmonary medicine.
- Healthcare providers managing patients with fibrotic interstitial lung disease.
Company Profile
Bellerophon Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Warren, US. The company is led by CEO Craig R. Jalbert CIRA. BLPH has traded publicly since 2015.
How Bellerophon Therapeutics, Inc. Is Valued
Relative to its peer group, BLPH's quantitative score of 44/100 is below the peer average of 73/100.
F-Score 2/9Financial Health
Bellerophon Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project Bellerophon Therapeutics, Inc. revenue of about $232.3M for fiscal 2026, with EPS near $3.63.
BLPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Bellerophon's recent insider buying suggests those in the know see long-term value, mirroring situations like company officers loading up on Apple before major product launches.
- The buzz in trading communities hints at growing excitement around their pipeline, similar to the early hype surrounding CRISPR gene editing stocks.
- The market seems to be warming up to Bellerophon's strategic focus, a shift in perception akin to investors recognizing the potential in Tesla's energy solutions beyond just cars.
- Positive whispers about potential partnerships could signal upcoming catalysts, much like the market anticipation before Gilead's major acquisitions.
Bear Case
- Skeptics question the speed of Bellerophon's clinical trial progress, drawing parallels to the slow development cycles that have plagued some biotech firms.
- Despite the positive sentiment, there's underlying concern about the company's cash burn rate, reminiscent of worries surrounding WeWork's unsustainable growth.
- Some community members express doubts about the broad applicability of their current technology, echoing the market's initial hesitation towards novel drug delivery systems.
- Negative chatter suggests potential regulatory hurdles down the line, similar to the challenges faced by cannabis companies navigating evolving legal landscapes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BLPH Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Aug 23, 2021
BLPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BLPH.
Price Targets
Wall Street price target analysis for BLPH.
BLPH MoonshotScore
What does this score mean?
The MoonshotScore rates BLPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Craig R. Jalbert CIRA
CEO
Craig R. Jalbert is the Chief Executive Officer of Bellerophon Therapeutics. His background includes extensive experience in the pharmaceutical and biotechnology industries. He is a Certified Insolvency and Restructuring Advisor (CIRA). Jalbert's expertise spans financial management, strategic planning, and operational execution within the healthcare sector. His leadership is focused on driving the clinical development and commercialization of innovative therapies for cardiopulmonary diseases.
Track Record: Under Jalbert's leadership, Bellerophon Therapeutics has advanced the clinical development of INOpulse, including the ongoing Phase 3 trial for pulmonary hypertension associated with fibrotic interstitial lung disease. He has also overseen the company's efforts to secure funding and navigate the regulatory landscape. His strategic decisions have been instrumental in positioning Bellerophon as a key player in the pulmonary hypertension market.
BLPH Healthcare Stock FAQ
What does the AI Score mean for BLPH?
BLPH holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiopulmonary diseases. Their lead product candidate, INOpulse, is a …
What does Bellerophon Therapeutics, Inc. do?
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiopulmonary diseases, particularly pulmonary hypertension. Their lead product candidate, INOpulse, is a proprietary pulsatile nitric oxide delivery system designed to improve the efficacy and safety of nitric oxide therapy.
What do analysts say about BLPH stock?
Given Bellerophon's clinical-stage status and focus on a single product candidate, INOpulse, analyst opinions are highly sensitive to clinical trial outcomes and regulatory milestones. The company's valuation is largely dependent on the successful development and commercialization of INOpulse.
What are the main risks for BLPH?
The primary risks for Bellerophon Therapeutics include the potential failure of the Phase 3 clinical trial of INOpulse, regulatory delays or rejection by the FDA and other agencies, competition from existing and emerging therapies for pulmonary hypertension, and the need to raise additional capital to fund clinical development and commercialization activities.
What are the key factors to evaluate for BLPH?
Bellerophon Therapeutics, Inc. (BLPH) holds an AI score of 44/100 (low). Not financial advice.
How frequently does BLPH data refresh on this page?
BLPH's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BLPH's recent stock price performance?
Bellerophon Therapeutics, Inc. (BLPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary INOpulse technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BLPH overvalued or undervalued right now?
Bellerophon Therapeutics, Inc. (BLPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BLPH before investing?
Before investing in Bellerophon Therapeutics, Inc. (BLPH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and company filings.
- Clinical trial outcomes are inherently uncertain and may differ from expectations.
- This is not investment advice. Conduct thorough research before making any investment decisions.